Trial Search Results
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
Stanford is currently not accepting patients for this trial.
Catalyst Pharmaceuticals, Inc.
- Drug: Amifampridine Phosphate
- Drug: Placebo
Inclusion Criteria: Individuals eligible to participate in this study must meet all of the
following inclusion criteria:
- ≥18 years of age
- Confirmed diagnosis of LEMS
- Normal respiratory function
- Normal swallowing function
- If receiving peripherally acting cholinesterase inhibitors a stable dose is required
for at least 7 days prior to Screening.
- If receiving oral immunosuppressants a stable dose is required for at least 90 days
prior to Screening.
- Negative pregnancy test for females of childbearing potential
- If sexually active, willing to use 2 acceptable methods of contraception
- Willing to perform all study procedures as physically possible.
- Willing and able to provide written informed consent after the nature of the study has
been explained and prior to the start of any research-related procedures.
Exclusion Criteria: Individuals who meet any of the following exclusion criteria are not
eligible to participate in the study:
- History of epilepsy or seizure.
- Known active brain metastasis.
- Use of Fampridine (4-aminopyridine), and any form of 3,4-diaminopyridine other than
the IP provided, such as amifampridine base or Firdapse, during the study.
- Use of medications known to lower the epileptic threshold within 7 days or 5
- Use of medications which inhibit neuromuscular junction function within 7 days or 5
- Use of IVIG, plasmapheresis (plasma exchange), or immunoadsorption within 90 days
- Use of guanidine hydrochloride within 7 days
- Use of rituximab within 12 months
- History of drug allergy to any pyridine-containing substances or any amifampridine
- Use of any other investigational productwithin 30 days
- Treatment with a concomitant medication that prolongs the QT/QTc interval within 7
days or 5 half-lives.
- Treatment with sultopride
- An abnormal electrocardiogram (ECG).
- Documented history of arrhythmias.
- History of additional risk factors for torsade de pointes.
- Breastfeeding or pregnant or planning to become pregnant (self or partner) at any time
during the study.
- Likely or expected to require treatment for cancer within 3 months (90 days) after
- History of severe renal impairment or evidence of severe renal impairment
- Any condition that places the patient at high risk of poor treatment compliance or of
not completing the study.
- History of uncontrolled asthma.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study